Scilex signs binding term sheet for $100M from Kazakhstan's iHolding at a premium
What's the deal? Scilex HoldingDealroom has a profile for this one. Try Dealroom → (Nasdaq: SCLX) has signed a binding term sheet for a proposed $100 million strategic investment from iHolding Group, a private investment group based in Almaty, Kazakhstan. Under the deal, iHolding would buy newly issued Scilex common stock at $15.00 per share — roughly 6,666,667 shares.
What does Scilex do? The Palo Alto-based company develops and commercialises non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic disease.
Why it matters: The $15.00 purchase price marks a sharp step-up from Scilex's recent trading levels, signalling investor conviction at a premium to where the stock had priced.
What's the endgame? The raise fits a broader pattern of Scilex dealmaking. In 2025–2026, it deployed capital outward, including a $150 million strategic investment in Datavault AIDealroom has a profile for this one. Try Dealroom →, part of which closed in September 2025, and a $20 million investment in Quantum Scan Holdings announced in January 2026.
What could go wrong? The term sheet is binding but preliminary, and terms such as pricing are described as "expected" rather than final. Comparable Scilex transactions, like the Datavault deal, were structured in tranches and tied to equity issuance and stockholder approval — steps that can slow or reshape a deal.
The signal: Scilex is increasingly leaning into treasury-style investments and portfolio building alongside its core biopharma franchise. For investors, the run of cross-sector dealmaking — now paired with a premium-priced inbound raise — may matter as much as the pain-drug business itself.
Read more: GlobeNewswire
Image credit: foteih
